TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10576122
Drug: Recombinant interleukin-2
Normalized name: Recombinant interleukin-2 human
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Recombinant interleukin-2 (rIL-2) treatment
Study: 8896528
Drug: Control whole
Normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control whole cell vaccine
Study: 1665490
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion chemotherapy with doxorubicin and ifosfamide
Study: 1665490
Drug: Intravenous bolus
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bolus chemotherapy with doxorubicin and ifosfamide
Study: 6342842
Drug: sotalol 320
Normalized name: sotalol 320 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: sotalol 320 mg once daily
Study: 28159671
Drug: Antibiotic checklist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic checklist intervention
Study: 23936981
Drug: Ferrous fumarate
Normalized name: Ferrous Fumarate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous fumarate 200 mg/day
Study: 23936981
Drug: Ferrous fumarate
Normalized name: Ferrous Fumarate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous fumarate 200 mg/day + Ascorbic acid 100 mg/day
Study: 23936981
Drug: Ferrous fumarate
Normalized name: Ferrous Fumarate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous fumarate 200 mg/day + Ascorbic acid 500 mg/day
Study: 19959335
Drug: Bupivacaine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine (10 cc of 2.5mg/cc with 1:80.000 epinephrine)
Study: 18260764
Drug: 15 microg
Normalized name: Tafluprost 15 microgram/mL eye drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 microg of vaccine per dose with MF59
Study: 18260764
Drug: 45 microg
Normalized name: Linaclotide 145 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 45 microg per dose of vaccine alone
Study: 18260764
Drug: Vaccine at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine at 15 or 7.5 microg per dose with MF59
Study: 18260764
Drug: Vaccine at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine at 30, 15, or 7.5 microg per dose with aluminum hydroxide
Study: 16809802
Drug: Methoxsalen (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methoxsalen (40 mg)
Study: 16809802
Drug: Cyclosporine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine (200 mg)
Study: 14570793
Drug: Sequential Compression
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential Compression Device (SCD) with thigh-high sleeves at a preset pressure of 50 mm Hg
Study: 8627582
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg tirilazad mesylate solution orally with 200 mg ketoconazole once daily
Study: 8627582
Drug: 2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg i.v. tirilazad mesylate solution with 200 mg ketoconazole once daily
Study: 8627582
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg tirilazad mesylate solution orally
Study: 8627582
Drug: 2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg i.v. tirilazad mesylate solution
Study: 1360277
Drug: 400 mg/day
Normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg/day of azidothymidine (AZT), group A
Study: 1360277
Drug: 800 mg/day
Normalized name: RibaTab 800 mg/day Compliance Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg/day of azidothymidine (AZT), group B
Study: 3881645
Drug: Soluble insulin
Normalized name: Soluble insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Soluble insulin at 10 U/mL
Study: 3881645
Drug: Soluble insulin
Normalized name: Soluble insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Soluble insulin at 40 U/mL
Study: 3881645
Drug: Soluble insulin
Normalized name: Soluble insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Soluble insulin at 100 U/mL
Study: 3881645
Drug: Bolus SC
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus SC injection of soluble insulin at 40 U/mL
Study: 20483887
Drug: Quarter dose
Normalized name: Quarter Mate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quarter dose botulinum toxin A
Study: 20483887
Drug: Half dose
Normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half dose botulinum toxin A
Study: 20483887
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline injections (Control)
Study: 10214018
Drug: Topical prostaglandin
Normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical prostaglandin E1 (PGE1) 8 micrograms.g‐1
Study: 10214018
Drug: Topical prostaglandin
Normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical prostaglandin E1 (PGE1) 4 micrograms.g‐1
Study: 10214018
Drug: Topical prostaglandin
Normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical prostaglandin E1 (PGE1) 0 microgram.g‐1, 2 micrograms.g‐1, 4 micrograms.g‐1, and 8 micrograms.g‐1
Study: 526397
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of labetalol
Study: 526397
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of labetalol
Study: 17309377
Drug: FSN intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FSN intervention (needles inserted and swayed in the subcutaneous layer 200 times in 2 minutes)
Study: 15036490
Drug: peroral estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: peroral estradiol valerate 2 mg/day
Study: 15036490
Drug: transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: transdermal estradiol gel containing 1 mg estradiol/day
Study: 11804247
Drug: Trihydroxyethylrutosides (HR)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trihydroxyethylrutosides (HR) 300 mg, 2 tablets daily for 2 weeks
Study: 11804247
Drug: Trihydroxyethylrutosides (HR)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trihydroxyethylrutosides (HR) 300 mg, continued for another 2 weeks if symptoms persisted
Study: 2820619
Drug: Cyclic combination
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic combination of 2 mg oestradiol valerate (21 d) and 1 mg cyproterone acetate (11 d)
Study: 29540584
Drug: CBD 5
Normalized name: MENTHOL 0.06 g in 1 g TOPICAL GEL [Sombra Plus CBD 500MG Cool Therapy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBD 5 mg/kg/d
Study: 29540584
Drug: CBD 10
Normalized name: MENTHOL 0.06 g in 1 g TOPICAL GEL [SOMBRA PLUS CBD 1000MG COOL THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBD 10 mg/kg/d
Study: 29540584
Drug: CBD 20
Normalized name: MENTHOL 0.06 g in 1 g TOPICAL GEL [SOMBRA PLUS CBD 2000MG COOL THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBD 20 mg/kg/d
Study: 22035956
Drug: Oral nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nutritional supplements as needed until three months after hip fracture surgery
Study: 20142336
Drug: 2-injection technique
Normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-injection technique (group 1, n = 56)
Study: 20142336
Drug: 4-injection technique
Normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-injection technique (group 2, n = 58)
Study: 17432681
Drug: Xuezhikang (XZK)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xuezhikang (XZK) plus standard CHF treatment (angiotensin converting enzyme inhibitor, beta‐receptor inhibitor, digoxin, diuretic) for six months
Study: 17432681
Drug: Standard CHF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard CHF treatment (angiotensin converting enzyme inhibitor, beta‐receptor inhibitor, digoxin, diuretic)
Study: 16398773
Drug: 400 microg
Normalized name: Fentanyl 400 microgram buccal film
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 microg oral misoprostol
Study: 7743295
Drug: Curosurf (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curosurf (200 mg/kg initial dose; up to two additional doses of 100 mg/kg after 12 and 24 hours if needed)
Study: 7743295
Drug: Survanta (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Survanta (100 mg/kg initial dose; up to three additional doses of 100 mg/kg between six and 48 hours if needed)
Study: 28842733
Drug: Low-dose KHCO3
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose KHCO3 (1 mmol/kg/day)
Study: 28842733
Drug: High-dose KHCO3
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose KHCO3 (1.5 mmol/kg/day)
Study: 24086581
Drug: Therapeutic education
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic education on antibiotic use delivered by a pharmacist (30-minute face-to-face session).
Study: 24086581
Drug: Therapeutic education
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic education on antibiotic use (intervention group).
Study: 21846460
Drug: FRP combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: FRP combined with metronidazole and amoxicillin
Study: 21846460
Drug: Systemic use
Normalized name: Psoralens for systemic use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic use of metronidazole and amoxicillin or doxycycline
Study: 19125434
Drug: Probiotic treatment
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic treatment in severe pancreatitis
Study: 17596104
Drug: Bevirimat (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevirimat (25 mg, 50 mg, 75 mg with 150 mg loading dose, 100 mg, 150 mg, 200 mg)
Study: 12964231
Drug: Emla (lignocaine/prilocaine)
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Emla (lignocaine/prilocaine) anaesthetic cream
Study: 7509495
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg risperidone
Study: 7509495
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg risperidone
Study: 7509495
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg clozapine
Study: 1970907
Drug: Pseudoephedrine 60
Normalized name: CTM 4/PSEUDOEPHEDRINE 60MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pseudoephedrine 60 mg
Study: 8721493
Drug: Saline injections
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline injections (control)
Study: 28368334
Drug: High protein
Normalized name: Vital High Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: High protein and fiber (HPHF; HP = 25 g, HF = 8 g)
Study: 28368334
Drug: Normal protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal protein and high fiber (NPHF; NP = 12.5 g, HF = 8 g)
Study: 28368334
Drug: High protein
Normalized name: Vital High Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: High protein and normal fiber (HPNF; HP = 25 g, NF = 2 g)
Study: 28368334
Drug: Normal protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal protein and fiber (NPNF; NP = 12.5 g, NF = 2 g)
Study: 16446323
Drug: BAY 43‐9006
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY 43‐9006 (sorafenib) 400 mg orally twice daily
Study: 7994792
Drug: Intravesical instillation
Normalized name: ADSTILADRIN Suspension for Intravesical Instillation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical instillation of Adriamycin (ADM) plus verapamil (VR) (30 mg/24 ml physiological saline + 15 mg/6 ml saline)
Study: 7994792
Drug: Intravesical instillation
Normalized name: ADSTILADRIN Suspension for Intravesical Instillation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical instillation of Adriamycin (ADM) alone (30 mg/30 ml physiological saline)
Study: 2838926
Drug: 5000 IU
Normalized name: D 5000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5000 IU conventional heparin
Study: 2838926
Drug: 5000 anti‐Xa
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5000 anti‐Xa U of low molecular weight heparin (Fragmin)
Study: 26165736
Drug: Intravenous proton
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous proton pump inhibitor (PPI) before ESD
Study: 26165736
Drug: No intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: No intravenous proton pump inhibitor (PPI) before ESD
Study: 21943845
Drug: Early antiretroviral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early antiretroviral treatment (ART) initiated before 12 weeks
Study: 3310563
Drug: Maximum activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maximum activity of aspartate aminotransferase (ASAT), analyzed once daily for 3 days
Study: 31954063
Drug: Oral stimulation
Normalized name: follicle stimulating hormone / luteinizing hormone Injection [Menopur]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral stimulation
Study: 26846612
Drug: Cognitive-behavioural therapy-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioural therapy-based psychoeducation
Study: 23909846
Drug: Topical indometacin
Normalized name: indometacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical indometacin applied immediately post-PDT
Study: 23909846
Drug: Intradermal injection
Normalized name: Dryvax Intradermal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal injection of l-NAME into 5-ALA-PDT-treated sites
Study: 16552410
Drug: Dietary supplement
Normalized name: dietary supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary supplement with 40 mg/day ephedra alkaloids and 100 mg/day caffeine
Study: 27227930
Drug: Control supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control supplement
Study: 16552410
Drug: Dietary supplement
Normalized name: dietary supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary supplement with ephedra and caffeine
Study: 14559886
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (ondansetron and dexamethasone on day 1; dexamethasone on days 2 to 4)
Study: 1421625
Drug: Ofloxacin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin (200 mg b.i.d. for 10 days)
Study: 1421625
Drug: Fleroxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fleroxacin (400 mg s.i.d. for 7 days)
Study: 1421625
Drug: Fleroxacin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fleroxacin (600 mg s.i.d. for 7 days)
Study: 24104875
Drug: Doxycycline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (100 mg b.i.d. for 7 days)
Study: 1421625
Drug: Ofloxacin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin (200 mg single dose)
Study: 30089602
Drug: Erlotinib 150
Normalized name: erlotinib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib 150 mg oral daily plus 500 mg intramuscular fulvestrant on day 1, 15, 29 and every 28 days thereafter
Study: 30089602
Drug: Erlotinib alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib alone 150 mg oral daily
Study: 30089602
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (fulvestrant + erlotinib) in EGFR wild type patients
Study: 26727076
Drug: NNC0195‐0092 (0.02,
Approvals — FDA: no, EMA: no, PMDA: no
Description: NNC0195‐0092 (0.02, 0.04, 0.08, and 0.12 mg/kg)
Study: 26727076
Drug: NNC0195‐0092 (0.12
Approvals — FDA: no, EMA: no, PMDA: no
Description: NNC0195‐0092 (0.12 mg/kg)
Study: 26727076
Drug: NNC0195‐0092 (0.02
Approvals — FDA: no, EMA: no, PMDA: no
Description: NNC0195‐0092 (0.02 mg/kg and 0.04 mg/kg)
Study: 24535604
Drug: SPI-guided analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPI-guided analgesia (sufentanil bolus 10 μg when SPI > 50)
Study: 24535604
Drug: Standard practice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard practice (sufentanil administered according to standard clinical practice)
Study: 22798536
Drug: Cholecalciferol 10,333
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol 10,333 IU weekly
Study: 20109743
Drug: SQ-standardized grass
Approvals — FDA: no, EMA: no, PMDA: no
Description: SQ-standardized grass allergy immunotherapy tablet Grazax (Phleum pratense 75,000 SQ-T/2,800 BAU)
Study: 24160483
Drug: Monthly reminders
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly reminders for sit-to-stand activity
Study: 27770145
Drug: 186Re-HEDP administered
Normalized name: HEDP
DrugBank: Etidronic acid (DB01077)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 186Re-HEDP administered at levels above 3.5 GBq
Study: 27770145
Drug: Patient mean
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient mean absorbed dose
Study: 27770145
Drug: Whole-body absorbed
Normalized name: Insects (whole body), mite dermatophagoides farinae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-body absorbed dose
Study: 12161476
Drug: Daily hGH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily hGH therapy (6 mg/m2 weekly)
Study: 12161476
Drug: Alternate day
Normalized name: Alternaria alternata
DrugBank: Alternaria alternata (DB10424)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternate day hGH therapy (6 mg/m2 weekly)
Study: 12161476
Drug: Cumulative growth
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cumulative growth velocity over 4 years (2 years on and 2 years off therapy)
Study: 2140030
Drug: Prochlorperazine 5
Normalized name: prochlorperazine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prochlorperazine 5 mg intravenously
Study: 30664895
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy with 6 months of androgen deprivation therapy
Study: 30664895
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy without androgen deprivation therapy
Study: 16289980
Drug: Inhaled fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone propionate (FP) 1000 microg bid
Study: 18237866
Drug: Oral prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisone (P)
Study: 14695986
Drug: Acupuncture and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture and moxa treatment at therapeutic points
Study: 8818850
Drug: Co-amoxiclav (625
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-amoxiclav (625 mg three times daily for 10 days)
Study: 1430361
Drug: 15% paromomycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15% paromomycin sulfate and 12% methylbenzethonium chloride (15/12 P-ointment)
Study: 1430361
Drug: 15% paromomycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15% paromomycin sulfate and 5% methylbenzethonium chloride (15/5 P-ointment)
Study: 6100870
Drug: Enalapril (10-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (10-40 mg q.d.)
Study: 6100870
Drug: Enalapril (10-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (10-40 mg q.d.) + Hydrochlorothiazide (50 mg/day)
Study: 6100870
Drug: Enalapril (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (40 mg) + Hydrochlorothiazide (50, 25, 12.5 mg/day)
Study: 28766879
Drug: Bivalirudin (bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalirudin (bolus 0.75 mg/kg followed by infusion of 1.75 mg/kg, extra bolus 0.3 mg/kg before stenting)
Study: 28766879
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (UFH, 100 IU/kg)
Study: 26382728
Drug: 560 mg
Normalized name: spinosad 560 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 560 mg oral ibrutinib, fasting conditions
Study: 26382728
Drug: 560 mg
Normalized name: spinosad 560 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 560 mg oral ibrutinib, fed, after glucose drink
Study: 26382728
Drug: 140 mg
Normalized name: caffeine 140 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 140 mg oral ibrutinib, fed, with grapefruit juice before dosing
Study: 16943370
Drug: Rizatriptan 5
Normalized name: rizatriptan 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rizatriptan 5 mg
Study: 10220208
Drug: NPH-insulin (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPH-insulin (0.3 U/kg)
Study: 7045975
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Telepaque and Bilopaque (TF-B)
Study: 7045975
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Telepaque given with food (TF) and Telepaque given without food (TF-TF)
Study: 7045975
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Telepaque given without food (T) and Telepaque given without food (T-T)
Study: 31368269
Drug: Acupuncture plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture plus medication (Tamsulosin 0.2 mg/d for 8 weeks)
Study: 31368269
Drug: Medication (Tamsulosin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication (Tamsulosin 0.2 mg/d for 8 weeks)
Study: 20139678
Drug: DHA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA supplementation timing and dose
Study: 18341564
Drug: Lidocaine 20%
Normalized name: lidocaine 20% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 20% patch (DentiPatch)
Study: 12386637
Drug: Fixed 800
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed 800 mg/d ribavirin